Common Stock, $0.001 par value
- Symbol
- FBRX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Historical · closed Aug 27, 2026
Current Report · Items 7.01, 8.01, 9.01 · 8-K
Forte Biosciences, Inc.
Regulation FD Disclosure · Other Events
Item 7.01. Regulation FD Disclosure. On July 9, 2026, Forte Biosciences, Inc. (the “Company”) issued a press release announcing positive results from the FB102 double-blind placebo-controlled Phase 1b study in vitiligo. As part of the press release, the Company announced that it would be hosting a conference call at 8:30 a.m. ET on July 9, 2026 to review the study results.…
Company context
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (Regulation 596/2014).
Historical securities (1)
Registered securities in this filing
FORTE BIOSCIENCES, INC. · 8-K · Filed 2026-07-09
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On July 9, 2026, Forte Biosciences, Inc. (the “Company”) issued a press release announcing positive results from the FB102 double-blind placebo-controlled Phase 1b study in vitiligo. As part of the press release, the Company announced that it would be hosting a conference call at 8:30 a.m. ET on July 9, 2026 to review the study results. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
All of the information furnished in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
In connection with the conference call to review the Phase 1b study results, the Company will be reviewing the FB102 Phase 1B Vitiligo Data Presentation attached hereto as Exhibit 99.2, which is incorporated herein by reference.
Filed exhibits (2)
EX-99.1 2 d170175dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 FB102 ACHIEVES STATISTICALLY SIGNIFICANT IMPROVEMENT IN VITILIGO AT WEEK 24 AFTER COMPLETION OF 12-WEEK TREATMENT PERIOD Statistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24 FB102-Treated Subjects Continued Improving Through Week 24 After Completion of the 12-Week Treatment Period Supporting FB102 Mechanistic Modulation of Both IL-2 - and IL-15 - Dependent Pathogenic T-cell Biology while Preserving Regulatory T Cells Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET DALLAS, TX - JULY 9, 2026 - Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: FB102 achieved 29.6% mean FVASI improvement from baseline at week 24 (p-value = 0.020) Response to FB102 was observed early, with statistically significant improvements observed by the day 64 visit (p=0.023), continuing through week 24, after completion of the 12-week treatment period. FB1…
Open exhibit ↗EX-99.2 3 d170175dex992.htm EX-99.2 EX-99.2 Forte FB102 Phase 1b Vitiligo Data July 9, 2026 Exhibit 99.2 Cautionary Note Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 2IE of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, known as the PSLRA. These include statements regarding management's intention, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Forte Biosciences, Inc. ("we", the "Company" or "Forte") undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as "anticipates," "believes," "plans," "expects," "projects," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance," and similar expressio…
Open exhibit ↗